Summary
Drug development targeting CD137 has been historically fraught because of concerns over safety and efficacy. A deeper understanding of CD137 function and insights into why earlier CD137 agonists failed have set the stage for a new generation of promising CD137 therapeutics.
This content is only available via PDF.
©2025 American Association for Cancer Research
2025
American Association for Cancer Research
You do not currently have access to this content.